The trial accomplished equally its Major endpoints, with semaglutide two.4 mg demonstrating statistically major and superior improvements in liver fibrosis without worsening of steatohepatitis, and resolution of steatohepatitis without any worsening of liver fibrosis in those with MASH when compared with placebo.oneSeveral behaviors and Way of life